The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, provides insight into the MAVRiC trial (NCT07024706), an upcoming Phase II trial that will investigate the efficacy of retreatment with acalabrutinib plus venetoclax (AV) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have relapsed after first-line finite-duration therapy with a BTK inhibitor (BTKi) plus venetoclax (ven)-based combination. Dr Davids highlights that the study’s unique aspect is the use of IGHV mutational status to determine therapy duration. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
